# EDGAR Filing Document

**Accession Number:** 0001697532
**File Stem:** 0001104659-23-025347
**Filing Date:** 2023-2
**Character Count:** 4755
**Document Hash:** 7b3543c625907b96c294ee834e9149a8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-025347.hdr.sgml**: 20230224

**ACCESSION NUMBER**: 0001104659-23-025347

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20230217

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**FILED AS OF DATE**: 20230224

**DATE AS OF CHANGE**: 20230224

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Applied Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001697532
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38898
- **FILM NUMBER:** 23668148

**BUSINESS ADDRESS:**
- **STREET 1:** 545 5TH AVENUE, SUITE 1400
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
- **BUSINESS PHONE:** 212-220-9319

**MAIL ADDRESS:**
- **STREET 1:** 545 5TH AVENUE, SUITE 1400
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017

?xml version="1.0" encoding="utf-8"?

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **February 17, 2023**

**APPLIED THERAPEUTICS, INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-38898** | **81-3405262** |
| (State or Other Jurisdiction of<br> Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |

---

---

| | |
|:---|:---|
| **545 Fifth Avenue, Suite 1400<br> New York, NY 10017** | **10017** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **(212) 220-9226**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

---

| |
|:---|
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

---

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp; **Title of each class** | &nbsp;&nbsp; **Trading Symbol(s)** | &nbsp;&nbsp; **Name of each exchange on which<br> registered** |
| &nbsp;&nbsp;Common stock | &nbsp;&nbsp;APLT | &nbsp;&nbsp;The Nasdaq Global Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ⌧

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp;&nbsp;&nbsp; x

**Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.** 

On February 17, 2023, Chids Mahadevan notified Applied Therapeutics, Inc. (the "Company") that he will resign from his position as the Company's Vice President of Finance and interim Principal Financial Officer, effective as of February 24, 2023, to pursue another professional opportunity. In connection with his departure, Mr. Mahadevan will be entitled to receive payment of his discretionary cash bonus with respect to 2022, subject to a customary release of claims. The Company has appointed Steven Ortega, Chief Accounting Officer, as the interim Principal Financial Officer, effective immediately, in light of Mr. Mahadevan's anticipated departure.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **APPLIED THERAPEUTICS, INC.** | **APPLIED THERAPEUTICS, INC.** |
| Dated: February 24, 2022 | By: | */s/ Shoshana Shendelman* |
|  | Name: | Shoshana Shendelman. |
|  | Title: | President and Chief Executive Officer |

---